imatinib mesylate has been researched along with Cholera Infantum in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, C; Jin, L; Li, J; Lv, Y; Pan, P; Shen, L; Sun, C; Sun, M; Wang, L; Wang, Y; Xue, Z; Yao, Y; Zhang, A; Zheng, P | 1 |
| Erben, P; Fabarius, A; Griesshammer, M; Hehlmann, R; Hochhaus, A; Hofmann, WK; Lengfelder, E; Merx, K; Reiter, A | 1 |
| Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE | 1 |
| Dickinson, TM; Jones, CM; Salvado, A | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Daniels, CE; Gabor, E; Lasky, JA; Limper, AH; Mieras, K; Schroeder, DR | 1 |
| Schiffer, CA; Zonder, JA | 1 |
| Brümmendorf, TH; Keller-V Amsberg, G | 1 |
| Arteaga, CL; Roberts, RB; Threadgill, DW | 1 |
| Camilleri, M | 1 |
| Hochhaus, A; Schmitt-Graeff, A | 1 |
| Belani, CP; Doroshow, JH; Egorin, MJ; Grem, JL; Hamilton, A; Hayes, MJ; Ivy, SP; LoRusso, PA; Mulkerin, DL; Murgo, AJ; Peng, B; Potter, DM; Ramanathan, RK; Remick, SC; Takimoto, CH | 1 |
5 review(s) available for imatinib mesylate and Cholera Infantum
| Article | Year |
|---|---|
Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2020 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Biological Availability; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Pharmacovigilance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Treatment Outcome | 2012 |
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cardiomyoplasty; Colorectal Neoplasms; Cyclooxygenase 2; Disease Models, Animal; ErbB Receptors; Gastrointestinal Diseases; Genes, abl; Genetic Engineering; Humans; Imatinib Mesylate; Isoenzymes; Membrane Proteins; Mice; Mice, Transgenic; Neoplasms; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; Skin Abnormalities; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
GI clinical research 2002-2003: the year in review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Benzamides; Biomedical Research; Colorectal Neoplasms; Gastrointestinal Diseases; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Imatinib Mesylate; Irritable Bowel Syndrome; Peptic Ulcer Hemorrhage; Piperazines; Pyrimidines; Risk Factors; Stomach Neoplasms | 2003 |
6 trial(s) available for imatinib mesylate and Cholera Infantum
| Article | Year |
|---|---|
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Topics: Aged; Aged, 80 and over; Benzamides; Bone Marrow; Combined Modality Therapy; Female; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Janus Kinase 2; Leukocyte Count; Male; Middle Aged; Mutation, Missense; Organ Size; Pain; Phlebotomy; Piperazines; Point Mutation; Polycythemia Vera; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Spleen; Treatment Outcome | 2013 |
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Treatment Outcome; Young Adult | 2013 |
Phase II open label trial of imatinib in polycythemia rubra vera.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematocrit; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Remission Induction; Skin Diseases | 2008 |
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Topics: Aged; Anemia; Benzamides; Disease Progression; Double-Blind Method; Dyspnea; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematoma, Subdural; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Leukopenia; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2010 |
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bilirubin; Female; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Liver Diseases; Liver Function Tests; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines | 2008 |
1 other study(ies) available for imatinib mesylate and Cholera Infantum
| Article | Year |
|---|---|
[Hematological side effects of tyrosine kinase inhibition using imatinib].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Gastrointestinal Diseases; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |